OncoGenex Pharmaceuticals Inc. (NASDAQ:ACHV) Upgraded at ValuEngine
ValuEngine upgraded shares of OncoGenex Pharmaceuticals Inc. (NASDAQ:ACHV) from a sell rating to a hold rating in a research note released on Friday.
OncoGenex Pharmaceuticals (NASDAQ:ACHV) opened at 4.1573 on Friday. OncoGenex Pharmaceuticals has a one year low of $3.61 and a one year high of $10.67. The company’s market cap is $11.37 million.
OncoGenex Pharmaceuticals (NASDAQ:ACHV) last issued its earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter.
COPYRIGHT VIOLATION NOTICE: “OncoGenex Pharmaceuticals Inc. (NASDAQ:ACHV) Upgraded at ValuEngine” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/07/oncogenex-pharmaceuticals-inc-nasdaqachv-upgraded-at-valuengine.html.
About OncoGenex Pharmaceuticals
Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.